Growth Hormone Axis and Aging

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 2, 2013, Pages 187-199

  Nass, Ralf ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aging; Ghrelin mimetic; Growth hormone

Indexed keywords

ALENDRONIC ACID; CAPROMORELIN; GHRELIN; GHRELIN MIMETIC; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; IBUTAMOREN; PLACEBO; SOMATOMEDIN C; SOMATOSTATIN; SUN 11031; UNCLASSIFIED DRUG;

AGING; ARTHRALGIA; BODY COMPOSITION; BONE DENSITY; CANCER RISK; CARPAL TUNNEL SYNDROME; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ELDERLY CARE; FEMUR NECK; FRAIL ELDERLY; FUNCTIONAL STATUS; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GYNECOMASTIA; HIP; HORMONE SUBSTITUTION; HUMAN; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIFESPAN; LUMBAR SPINE; MUSCLE FUNCTION; MUSCLE MASS; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOPENIA; SIDE EFFECT; TREATMENT OUTCOME;

AGING; ANIMALS; GHRELIN; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; MUSCULOSKELETAL DEVELOPMENT; MUSCULOSKELETAL PHYSIOLOGICAL PHENOMENA; PITUITARY GLAND, ANTERIOR; SARCOPENIA;

EID: 84878158386     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.02.001     Document Type: Review

References (94)

1. CDC. Public health and aging: trends in aging-United States and Worldwide. JAMA 2003, 289:1371-1373.
2. Gullberg B., Johnell O., Kanis J.A. World-wide projections for hip fracture. Osteoporos Int 1997, 7:407-413.
3. Tinetti M.E., Baker D.I., McAvay G., et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994, 331(13):821-827.
4. Hartman M.L., Faria A.C., Vance M.L., et al. Temporal structure of in vivo growth hormone secretory events in humans. Am J Physiol 1991, 260(1 Pt 1):E101-E110.
5. Thorner M.O., Chapman I.M., Gaylinn B.D., et al. Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging. Recent Prog Horm Res 1997, 52:215-244. [discussion: 244-6].
6. Wagner C., Caplan S.R., Tannenbaum G.S. Interactions of ghrelin signaling pathways with the GH neuroendocrine axis: a new and experimentally tested model. J Mol Endocrinol 2009, 43(3):105-119.
7. Van Cauter E., Plat L., Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998, 21(6):553-566.
8. Vance M.L., Kaiser D.L., Evans W.S., et al. Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion. J Clin Invest 1985, 75(5):1584-1590.
9. Webb C.B., Vance M.L., Thorner M.O., et al. Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation. J Clin Invest 1984, 74(1):96-103.
10. Dimaraki E.V., Jaffe C.A., Demott-Friberg R., et al. Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator. Am J Physiol Endocrinol Metab 2001, 280(3):E489-E495.
11. Maheshwari H.G., Pezzoli S.S., Rahim A., et al. Pulsatile growth hormone secretion persists in genetic growth hormone-releasing hormone resistance. Am J Physiol Endocrinol Metab 2002, 282(4):E943-E951.
12. Muller E.E., Locatelli V., Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 1999, 79(2):511-607.
13. Frohman L.A., Downs T.R., Clarke I.J., et al. Measurement of growth hormone-releasing hormone and somatostatin in hypothalamic-portal plasma of unanesthetized sheep. Spontaneous secretion and response to insulin-induced hypoglycemia. J Clin Invest 1990, 86(1):17-24.
14. Mano-Otagiri A., Nemoto T., Sekino A., et al. Growth hormone-releasing hormone (GHRH) neurons in the arcuate nucleus (Arc) of the hypothalamus are decreased in transgenic rats whose expression of ghrelin receptor is attenuated: Evidence that ghrelin receptor is involved in the up-regulation of GHRH expression in the arc. Endocrinology 2006, 147(9):4093-4103.
15. Koutkia P., Canavan B., Breu J., et al. Nocturnal ghrelin pulsatility and response to growth hormone secretagogues in healthy men. Am J Physiol Endocrinol Metab 2004, 287(3):E506-E512.
16. Avram A.M., Jaffe C.A., Symons K.V., et al. Endogenous circulating ghrelin does not mediate growth hormone rhythmicity or response to fasting. J Clin Endocrinol Metab 2005, 90(5):2982-2987.
17. Muller A.F., Lamberts S.W., Janssen J.A., et al. Ghrelin drives GH secretion during fasting in man. Eur J Endocrinol 2002, 146(2):203-207.
18. Misra M., Miller K.K., Kuo K., et al. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005, 289(2):E347-E356.
19. Espelund U., Hansen T.K., Hojlund K., et al. Fasting unmasks a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J Clin Endocrinol Metab 2005, 90(2):741-746.
20. Norrelund H., Hansen T.K., Orskov H., et al. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 2002, 57(4):539-546.
21. Nass R., Farhy L.S., Liu J., et al. Evidence for acyl-ghrelin modulation of growth hormone release in the fed state. J Clin Endocrinol Metab 2008, 93(5):1988-1994.
22. Nass R., Pezzoli S.S., Oliveri M.C., et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008, 149(9):601-611.
23. Pantel J., Legendre M., Cabrol S., et al. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest 2006, 116(3):760-768.
24. Sun Y., Wang P., Zheng H., et al. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 2004, 101(13):4679-4684.
25. Sun Y., Ahmed S., Smith R.G. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003, 23(22):7973-7981.
26. Zizzari P., Halem H., Taylor J., et al. Endogenous ghrelin regulates episodic growth hormone (GH) secretion by amplifying GH Pulse amplitude: evidence from antagonism of the GH secretagogue-R1a receptor. Endocrinology 2005, 146(9):3836-3842.
27. Finkelstein J.W., Roffwarg H.P., Boyar R.M., et al. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 1972, 35(5):665-670.
28. Zadik Z., Chalew S.A., McCarter R.J., et al. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J Clin Endocrinol Metab 1985, 60(3):513-516.
29. Novack L. Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years. J Gerontol 1972, 27:438-443.
30. Rudman D. Growth hormone, body composition, and aging. J Am Geriatr Soc 1985, 33(11):800-807.
31. Haarbo J., Marslew U., Gotfredsen A., et al. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991, 40(12):1323-1326.
32. Ashwell M., Cole T.J., Dixon A.K. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. Br Med J (Clin Res Ed) 1985, 290(6483):1692-1694.
33. DeNino W.F., Tchernof A., Dionne I.J., et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care 2001, 24(5):925-932.
34. Clasey J.L., Weltman A., Patrie J., et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab 2001, 86(8):3845-3852.
35. Enzi G., Gasparo M., Biondetti P., et al. Subcutaneous and visceral fat distribution according to sex, age and overweight, evaluated by computed tomography. Am J Clin Nutr 1986, 44:739-746.
36. Shimokata H., Tobin J., Muller D., et al. Studies in the distribution of body fat. I. Effects of age, sex, and obesity. J Gerontol 1989, 44:67-73.
37. Borkan G.A., Hults D.E., Gerzof S.G., et al. Age changes in body composition revealed by computed tomography. J Gerontol 1983, 38(6):673-677.
38. Marcus R. Skeletal aging-understanding the functional and structural basis of osteoporosis. Trends Endocrinol Metab 1991, 2:53-58.
39. Hannan M., Felson D., Anderson J. Bone mineral density in elderly men and women: results from the Framingham Osteoporosis Study. J Bone Miner Res 1992, 7:547-553.
40. Stiegler C., Leb G. One year of replacement therapy in adults with growth hormone deficiency. Endocrinol Metab 1994, 1(Suppl A):37-42.
41. Forbes G., Reina J. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970, 19:653-663.
42. Thompson J.L., Butterfield G.E., Marcus R., et al. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995, 80(6):1845-1852.
43. Janssen I., Heymsfield S.B., Wang Z.M., et al. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol 2000, 89(1):81-88.
44. Tseng B.S., Marsh D.R., Hamilton M.T., et al. Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging. J Gerontol A Biol Sci Med Sci 1995, 50(Spec No):113-119.
45. Bemben M.G., Massey B.H., Bemben D.A., et al. Isometric muscle force production as a function of age in healthy 20- to 74-yr-old men. Med Sci Sports Exerc 1991, 23(11):1302-1310.
46. Clement F.J. Longitudinal and cross-sectional assessments of age changes in physical strength as related to sex, social class, and mental ability. J Gerontol 1974, 29(4):423-429.
47. Hurley B.F. Age, gender, and muscular strength. J Gerontol A Biol Sci Med Sci 1995, 50(Spec No):41-44.
48. Kehayias J.J., Fiatarone M.A., Zhuang H., et al. Total body potassium and body fat: relevance to aging. Am J Clin Nutr 1997, 66(4):904-910.
49. Lexell J., Downham D., Sjostrom M. Distribution of different fibre types in human skeletal muscles. Fibre type arrangement in m. vastus lateralis from three groups of healthy men between 15 and 83 years. J Neurol Sci 1986, 72(2-3):211-222.
50. Doherty T.J. Invited review: aging and sarcopenia. J Appl Physiol 2003, 95(4):1717-1727.
51. Walston J., Hadley E.C., Ferrucci L., et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006, 54(6):991-1001.
52. Brown W.F. A method for estimating the number of motor units in thenar muscles and the changes in motor unit count with ageing. J Neurol Neurosurg Psychiatry 1972, 35(6):845-852.
53. Young V.R. Amino acids and proteins in relation to the nutrition of elderly people. Age Ageing 1990, 19(4):S10-S24.
54. Roubenoff R., Harris T.B., Abad L.W., et al. Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 1998, 53(1):M20-M26.
55. Argiles J.M., Busquets S., Felipe A., et al. Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol 2005, 37(5):1084-1104.
56. Delbono O. Molecular mechanisms and therapeutics of the deficit in specific force in ageing skeletal muscle. Biogerontology 2002, 3(5):265-270.
57. Gamper N., Fillon S., Huber S.M., et al. IGF-1 up-regulates K+ channels via PI3-kinase, PDK1 and SGK1. Pflugers Arch 2002, 443(4):625-634.
58. Labrie F., Belanger A., Luu-The V., et al. DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 1998, 63(5-6):322-328.
59. Janssen I., Heymsfield S.B., Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002, 50(5):889-896.
60. Marcus R., Butterfield G., Holloway L., et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990, 70:519-527.
61. Rudman D., Feller A., Nagraj H., et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990, 323:1-6.
62. Papadakis M.A., Grady D., Black D., et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996, 124(8):708-716. [see comments].
63. Taaffe D.R., Pruitt L., Reim J., et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994, 79(5):1361-1366.
64. Taaffe D.R., Thompson J.L., Butterfield G.E., et al. Recombinant human growth hormone, but not insulin-like growth factor-I, enhances central fat loss in postmenopausal women undergoing a diet and exercise program. Horm Metab Res 2001, 33(3):156-162.
65. Muenzer T., Harman S., Hees P., et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 2001, 86:3604-3610.
66. Kaiser F.E., Silver A.J., Morley J.E. The effect of recombinant human growth hormone on malnourished older individuals. J Am Geriatr Soc 1991, 39(3):235-240.
67. Lange K.H., Isaksson F., Rasmussen M.H., et al. GH administration and discontinuation in healthy elderly men: effects on body composition, GH-related serum markers, resting heart rate and resting oxygen uptake. Clin Endocrinol (Oxf) 2001, 55(1):77-86.
68. Liu H., Bravata D.M., Olkin I., et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007, 146(2):104-115.
69. Nass R, Liu J, Pezzoli SS, et al. 24-h mean acyl-ghrelin levels are decreased in older adults. 4th International Congress of the GRS and the IGF Society. Genova, September 19, 2008.
70. Rigamonti A.E., Pincelli A.I., Corra B., et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 2002, 175(1):R1-R5.
71. Nass R., Johannsson G., Christiansen J.S., et al. The aging population-is there a role for endocrine interventions?. Growth Horm IGF Res 2009, 19(2):89-100.
72. Sun Y., Garcia J.M., Smith R.G. Ghrelin and growth hormone secretagogue receptor expression in mice during aging. Endocrinology 2007, 148(3):1323-1329.
73. Broglio F., Benso A., Castiglioni C., et al. The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab 2003, 88(4):1537-1542.
74. Smith R.G. Development of growth hormone secretagogues. Endocr Rev 2005, 26(3):346-360.
75. Chapman I.M., Hartman M.L., Pezzoli S.S., et al. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback. J Clin Endocrinol Metab 1997, 82(9):2996-3004.
76. Murphy M.G., Weiss S., McClung M., et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001, 86(3):1116-1125.
77. Bach M.A., Rockwood K., Zetterberg C., et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc 2004, 52(4):516-523.
78. White H.K., Petrie C.D., Landschulz W., et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009, 94(4):1198-1206.
79. Monson J.P. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003, 148(Suppl 2):S9-S14.
80. Jenkins P.J., Mukherjee A., Shalet S.M. Does growth hormone cause cancer?. Clin Endocrinol (Oxf) 2006, 64(2):115-121.
81. Orme S.M., McNally R.J., Cartwright R.A., et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83(8):2730-2734.
82. Growth Hormone Research Society Consensus: critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001, 86:1868-1870.
83. van Bunderen C.C., van Nieuwpoort I.C., van Schoor N.M., et al. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab 2010, 95(10):4616-4624.
84. Roddam A.W., Allen N.E., Appleby P., et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008, 149(7):461-471. W83-8.
85. Holly J. Insulin-like growth factors (IGFs) and IGF binding proteins in PSA-detected prostate cancer: a population-based case control study. 5th International Congress of the GRS and IGF-I Society. New York, October 4, 2010.
86. Chipman J.J., Attanasio A.F., Birkett M.A., et al. The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 1997, 46(4):473-481.
87. Hwu C.M., Kwok C.F., Lai T.Y., et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997, 82(10):3285-3292.
88. Svensson J., Fowelin J., Landin K., et al. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002, 87(5):2121-2127.
89. Svensson J., Lonn L., Jansson J.O., et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998, 83(2):362-369.
90. Gertner J. SUN 11031 (synthetic human ghrelin) improves lean body mass and function in advanced COPD cachexia in a placebo controlled trial. 5th International Congress of the GRS and IGF-I Society. New York, October 4, 2010.
91. Bartke A. Long-lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. Trends Endocrinol Metab 2006, 17(2):33-35.
92. Berryman D.E., Christiansen J.S., Johannsson G., et al. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res 2008, 18(6):455-471.
93. Nass R., Thorner M.O. Life extension versus improving quality of life. Best Pract Res Clin Endocrinol Metab 2004, 18(3):381-391.
94. Besson A., Salemi S., Gallati S., et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab 2003, 88(8):3664-3667.